Ketamine-Induced Bladder Injury in Children: Clinical and Policy Implications

Paediatric Ketamine Bladder Injury: A New Clinical Signal

A recently published case report in August 2026 documents a pediatric patient developing bladder injury after ketamine exposure, marking one of the first such cases in the under-18 population (PubMed 42682967). While ketamine-associated cystitis is a recognized complication in adults, especially with frequent or high-dose use, pediatric cases have been virtually absent from the literature until now. This report underscores a potential emerging risk as ketamine is increasingly used both therapeutically and recreationally among younger populations.

The documented case involved a child presenting with lower urinary tract symptoms following ketamine exposure. Clinical findings were consistent with ketamine-induced cystitis, including bladder wall thickening and irritative symptoms. The authors note that, although this is an isolated report, it may represent the leading edge of a broader trend as access to ketamine expands.

Mechanisms of Ketamine Bladder Toxicity and Pediatric Vulnerability

Ketamine-induced bladder injury is believed to result from direct toxicity of ketamine and its metabolites on the urothelium (bladder lining), leading to inflammation, ulceration, and fibrosis. In adults, chronic or high-dose exposure is most strongly associated with cystitis, but the threshold for injury in children is unknown. Pediatric patients may have unique anatomical or metabolic susceptibilities, such as a thinner urothelium or differences in drug metabolism, that could lower the threshold for toxicity compared to adults.

Notably, the case report highlights that even limited or therapeutic exposure may carry risk in some pediatric patients—a non-obvious implication for clinicians accustomed to adult dosing paradigms. This finding suggests that pediatric patients should not be presumed to have the same safety profile as adults, and that age-specific pharmacovigilance is warranted.

Policy and Research Implications for Pediatric Ketamine Use

The emergence of pediatric bladder injury cases has immediate implications for clinical practice, research, and policy. First, clinicians prescribing ketamine for pain, anesthesia, or psychiatric indications in children should be aware of this potential adverse effect and consider implementing baseline and follow-up urinary tract monitoring. Second, institutional review boards (IRBs) and ethics committees overseeing pediatric ketamine trials may need to update risk disclosures and safety monitoring protocols in light of this new evidence.

• Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) may consider targeted post-marketing surveillance or risk evaluation and mitigation strategies (REMS) for pediatric ketamine use.
• Policy discussions regarding off-label ketamine use in minors—already a contentious topic—may be influenced by these findings, especially in jurisdictions considering expanded access or decriminalization.
• Research priorities now include prospective studies to quantify the incidence and risk factors for ketamine cystitis in pediatric populations, as well as mechanistic studies to elucidate age-specific vulnerabilities.

One insight not widely discussed is that even single or short-term ketamine exposures may pose risk for susceptible pediatric patients, challenging the assumption that only chronic use is problematic. This could influence both emergency medicine protocols and outpatient prescribing practices.

Risks, Unknowns, and the Need for Ongoing Surveillance

The main risk highlighted by this case is the potential for under-recognition of ketamine-induced bladder injury in children, particularly as symptoms may mimic common pediatric urinary tract disorders. The true incidence remains unknown, and there is a risk of both underdiagnosis and delayed intervention, which can lead to long-term bladder dysfunction.

Key unknowns include the minimum dose and duration required to induce injury in pediatric patients, potential genetic or metabolic risk factors, and the reversibility of symptoms after ketamine cessation. The lack of robust pediatric safety data underscores the need for systematic adverse event reporting and the inclusion of urinary tract endpoints in future pediatric ketamine trials.

Looking Forward: Balancing Access, Safety, and Research

As ketamine's therapeutic footprint expands, balancing access with safety will require proactive risk communication, updated clinical guidelines, and investment in pediatric-specific research. Stakeholders—including clinicians, regulators, and policymakers—should anticipate the need for age-adjusted monitoring protocols and informed consent language reflecting this emerging risk. Ongoing pharmacovigilance and transparent reporting will be critical to ensuring that the benefits of ketamine in pediatric populations are not undermined by preventable adverse effects.

How we research: This analysis was prepared and reviewed by Dr. Alex M. Greene, MD, MPH (Pediatric Clinical Pharmacology), on 2026-09-02. Primary source: PubMed 42682967. Regulatory and clinical context sourced from FDA, EMA, and NCBI guidelines as of August 2026.